HEALTH OF WOMAN. 2019.2(138): 91–95; doi 10.15574/HW.2019.138.91

Lakatosh V. P. , Kupchik V. I. , Guzhevskaya I. V. , Kostenko O. Yu. , Lakatosh P. V.
Bogomolets National Medical University, Kiev

The article presents an overview of native and foreign publications on atypical hemolytic-uremic syndrome. Modern terminology, classification is presented, questions about the causes and pathogenesis of this pathology are considered. The opinions of experts of obstetric and gynecological communities of the world on questions of clinics, diagnostics and treatment are given.

Key words: pregnancy, obstetric atypical hemolytic-uremic syndrome, eculizumab.

REFERENCES

1. Kirsanova TV, Merkusheva LI, Kozlovskaya NL, Fedorova TA i soavt. 2013. Atipichnyiy gemolitiko-uremicheskiy sindrom pri beremennosti: osobennosti techeniya, slozhnosti diagnostiki, podhodyi k terapii. Akusherstvo i ginekologiya 6: 70–75.

2. Kozlov LV. 2002. Issledovanie funktsionalnoy aktivnosti komponentov i faktorov sistemy komplementa cheloveka. Voprosyi meditsinskoy himii 48 (6): 624–631.

3. Kozlovskaya NL, Merkusheva LI, Kirsanova TV, Runihina NK. 2012. Osobennosti techeniya i ishoda atipichnogo gemolitiko-uremicheskogo sindroma pri beremennosti. Klinicheskaya nefrologiya 3: 44–49.

4. Kozlovskaya NL, Korotchaeva YuV. 2016. Atipichnyiy gemolitiko-uremicheskiy sindrom v akusherskoy praktike: pervyiy rossiyskiy opyit diagnostiki i lecheniya. Rossiyskiy vestnik akushera-ginekologa 6: 95–104.

5. Korotchaeva YuV, Kozlovskaya NL, Bondarenko TV, Veselov GA. 2015. «Akusherskiy» atipichnyiy gemolitiko-uremicheskiy sindrom: trudnyiy diagnoz? Arhiv akusherstva i ginekologii im. V.F. Snegireva. 2: 36–41.

6. Lora Sh, Fremyu-Bachi V. 2012. Atipichnyiy gemolitiko-uremicheskiy sindrom. Nefrologiya 16 (2): 16-46.

7. Prokopenko EI, Lihvantsev VV, Vatazin AV, Lopatin AF i soavt. 2016. Atipichnyiy gemolitiko-uremicheskiy sindrom, assotsiirovannyiy s beremennostyu: zhiznespasayuschaya terapiya ekulizumabom. Klinicheskaya nefrologiya 3:63–68.

8. Pyiregov AV, Fedorova TA, Korolev AYu, Grischuk KI. 2016. Atipichnyiy gemolitiko-uremicheskiy sindrom u patsientki s menometrorragiey (klinicheskoe nablyudenie). Vestnik anesteziologii i reanimatologii 13 (3):63–70.

9. Smirnov AV, Karunnaya AV, Dobronravov VA. 2017. Nefrologicheskie aspektyi komplement-oposredovannoy tromboticheskoy mikroangiopatii. Terapevticheskiy arhiv 89 (6): 34–40.

10. Ulitkina ON, Filippovskaya ZhS, Prokopenko EI, Ovezov AM i soavt. 2015. Uspeshnoe lechenie atipichnogo gemolitiko-uremicheskogo sindroma u rodilnitsyi. Obschaya reanimatologiya 11(6): 61–68.

11. Bao L, Quigg RJ. 2007. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol. 27 (1): 69–80. https://doi.org/10.1016/j.semnephrol.2006.09.009; PMid:17336690

12. Besbas N, Karpman D, Landau D et al. 2006. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70: 423–431. https://doi.org/10.1038/sj.ki.5001581; PMid:16775594

13. Burwick RM, Feinberg BB. 2013. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34: 201–203. https://doi.org/10.1016/j.placenta.2012.11.014; PMid:23228435

14. Campistol JM, Arias M, Ariceta G, Blasco M et al. 2015. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 35 (5): 421–447. https://doi.org/10.1016/j.nefro.2015.07.005; PMid:26456110

15. Caprioli J, Noris M, Brioschi S et al. 2006. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 108: 1267–79. https://doi.org/10.1182/blood-2005-10-007252; PMid:16621965 PMCid:PMC1895874

16. Cataland SR, Holers VM, Geyer S, Yang S et al. 2014. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood.123 (24):3733–8. https://doi.org/10.1182/blood-2013-12-547067; PMid:24695849

17. Cheong HI et al. 2016. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. Journal of Korean medical science 31 (10): 1516–28. https://doi.org/10.3346/jkms.2016.31.10.1516; PMid:27550478 PMCid:PMC4999392

18. Constantinescu AR, Bitzan M, Weiss LS et al. 2004. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am. J. Kidney Dis. 43: 976–982. https://doi.org/10.1053/j.ajkd.2004.02.010; PMid:15168377

19. Coppo P, Bussel A, Charrier S  et al. 2003. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 82: 27–38. https://doi.org/10.1097/00005792-200301000-00003; PMid:12544708

20. Demyanova KA, Kozlovskaya NL, Bobrova LA, Kozlov LV et al. 2017. Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome. Annals of the Russian Academy of Medical Sciences 72 (1): 42–52. https://doi.org/10.15690/vramn769; PMid:29308852

21. Fakhouri F, Roumenina L, Provot F et al. 2010. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 21 (5): 859–867. https://doi.org/10.1681/ASN.2009070706; PMid:20203157 PMCid:PMC2865741

22. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F et al. 2013. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8 (4): 554–562. https://doi.org/10.2215/CJN.04760512; PMid:23307876 PMCid:PMC3613948

23. Hofer J, Rosales A, Fischer C, Giner T. 2014. Extra-renal manifestations of complement-mediated thrombotic microangiopathiess. Front Pediatr.  2: 97. https://doi.org/10.3389/fped.2014.00097; PMid:25250305 PMCid:PMC4157546

24. Jokiranta TS. 2017. HUS and atypical HUS. Blood. 129 (21): 2847–56. https://doi.org/10.1182/blood-2016-11-709865; PMid:28416508 PMCid:PMC5445567

25. Kavanagh D, Richards A, Fremeaux-Bacchi V et al. 2007. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2 (3): 591–596. https://doi.org/10.2215/CJN.03270906; PMid:17699467

26. Kavanagh D, Goodship TH. 2011. Atypical hemolytic uremic syndrome, genetic basis and clinical manifesatations. Hematology Am. Soc. Hemat. Educ. Program.:15–17. https://doi.org/10.1182/asheducation-2011.1.15; PMid:22160007

27. Kavanagh D, Goodship TH. 2010. Atypical hemolytic uremic syndrome. Curr. Opin. Hematol. 17 (5): 432–438. https://doi.org/10.1097/MOH.0b013e32833cae86; PMid:20613506

28. Keating G.M. 2013. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 73: 2053–66. https://doi.org/10.1007/s40265-013-0147-7; PMid:24249647

29. Kourouklaris A, Ioannou K, Athanasiou L. 2014. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J. Med. Case. Rep. 8: 307. https://doi.org/10.1186/1752-1947-8-307; PMid:25219386 PMCid:PMC4170201

30. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M  et al. 2013. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45: 531–536. https://doi.org/10.1038/ng.2590; PMid:23542698 PMCid:PMC3719402

31. Licht C, Weyersberg A, Heinen S et al. 2005. Successful plasma therapy for atypicalhemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am. J. Kidney. Dis. 45: 415–21. https://doi.org/10.1053/j.ajkd.2004.10.018; PMid:15685522

32. Loirat C, Fakhouri F, Ariceta G, Besbas N et al. 2016. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 31 (2): 15–39. https://doi.org/10.1007/s00467-015-3076-8; PMid:25859752

33. Mackaness CA, Fleszler F. 2014. Eculizumab in the successful treatment of postpartum hemolytic uremic syndrome – a case report. Poster presented at the national kidney foundation, spring clinical meetings, Las Vegas: 22–24.

34. McMinn JR, George JN. 2001. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. CUn. Apker. 16: 202–209. https://doi.org/10.1002/jca.10005; PMid:11835417

35. Melis JP, Strumane K, Ruuls SR et al. 2015. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol.  67:117–130. https://doi.org/10.1016/j.molimm.2015.01.028; PMid:25697848

36. Meri S. 2013. Complement activation in diseases presenting with thrombotic microangiopathy. Eur. J. Intern. Med. 24 (6): 496–502. https://doi.org/10.1016/j.ejim.2013.05.009; PMid:23743117

37. Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. 2006. Secondary failure of plasma therapy in factor H deficiency. Pediatr. Nephrol.  21:1769–71. https://doi.org/10.1007/s00467-006-0237-9; PMid:16909242

38. Nester C, Stewart Z, Myers D et al. 2011. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 6 (6): 1488–94. https://doi.org/10.2215/CJN.10181110; PMid:21617085 PMCid:PMC3109948

39. Nester CM, Thomas CP. 2012. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? ASH Education Program Book 1: 617–625.

40. Noris M, Caprioli J, Bresin E, Mossali C et al. 2010. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5 (10): 1844–59. https://doi.org/10.2215/CJN.02210310
PMid:20595690 PMCid:PMC2974386

41. Noris M, Galbusera M, Gastoldi S et al. 2014. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124: 1715–26. https://doi.org/10.1182/blood-2014-02-558296; PMid:25037630 PMCid:PMC4162105

42. Novitzky N, Thomson J, Abrahams L, du Toit C et al. 2005.  Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br. J. Haematol. 128: 373–9. https://doi.org/10.1111/j.1365-2141.2004.05325.x; PMid:15667540

43. Rock GA, Shumak KH, Buskard NA et al. 1991. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 325: 393–7. https://doi.org/10.1056/NEJM199108083250604; PMid:2062330

44. Saad AF, Roman J, Wyble A, Pacheco LD. 2016. Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. AJP reports 6 (1): 125–8. https://doi.org/10.1055/s-0036-1579539; PMid:26989566 PMCid:PMC4794438

45. Shrivastava M. 2011. Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange. Transfus. Apheresis Sci. 44: 257–262. https://doi.org/10.1016/j.transci.2011.04.004; PMid:21550309

46. Shukevich DL, Peredelkin DK, Grigoryev EV, Razumov AS et al. 2010. Continuous renal replacement therapy for severe obstetric sepsis. General Reanimatology 4 (2): 21–24. https://doi.org/10.15360/1813-9779-2010-2-21

47. Tedesco F, Pausa M, Nardon E, Introna M et al. 1997. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185 (9): 1619–27. https://doi.org/10.1084/jem.185.9.1619; PMid:9151899

48. Wong Edwin KS, Kavanagh D. 2018. Diseases of complement dysregulation – an overview. Seminars in immunopathology 40 (1): 49–64. https://doi.org/10.1007/s00281-017-0663-8; PMid:29327071 PMCid:PMC5794843

49. Woodward L, Johnson S, Walle JV et al. 2016. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet J. Rare Dis. 11 (1): 154. https://doi.org/10.1186/s13023-016-0537-5; PMid:27871301 PMCid:PMC5117495